The latest news from academia, regulators
research labs and other things of interest
Posted: November 28, 2008
RCP Therapeutics Appoints Professor Weissig to its Scientifc Advisory Board
(Nanowerk News) RCP Therapeutics, a biopharmaceuticals company specialising in the converging nanotechnology and regenerative medical markets, announces the appointment of Professor Volkmar Weissig
to the Company’s Scientific Advisory Board.
Volkmar Weissig is Associate Professor of Pharmacology at the Department of Pharmaceutical
Sciences, Midwestern University College of Pharmacy, Glendale, Arizona, whilst previously serving
as Assistant Professor of Pharmaceutics at Northeastern University, Boston, Massachusetts. In
particular, the presence of Professor Weissig enhances RCP Therapeutics’ scientific expertise in
the field of nano-carrier assisted sub-cellular targeting and mitochondrial nanomedicine.
RCP Therapeutics has a lead therapeutic candidate that targets the mitochondria of cancer cells
to evade multi-drug resistance and this forms a core element of the company’s research and
The Company’s pioneering technology also treats injuries resulting from stroke ischemia and
reperfusion injury, which is expected to begin clinical trials in 2009. Furthermore, RCP
Therapeutics has identified and performed early stage trials using a p53 nanoparticle to treat the
effects of restenosis following angioplasty. The Company aggregates intellectual property,
performs early stage proof of concept in pre-clinical and clinical trials and seeks to penetrate
markets, and drives revenues through collaborative partnership with pharmaceutical companies in
later stage clinical studies.
To date, RCP Therapeutics has identified a series of product candidates and pilot launched first
product, Bimene, a novel nano-cosmeceutical skincare product, utilising its nanoparticle delivery
platform acquired via licenses from universities and US based research institutions.
Commenting on the appointment, Robert Sexauer: CEO of RCP Therapeutics expressed: “We
are very pleased that Professor Weissig is joining our Scientific Advisory Board, especially as he
is recognised as one of the pre-eminent scientists in the realm of sub-cellular targeting and
mitochondrial nanomedicine. Indeed, our company is driving innovations in this field. Professor
Weissig has been recently interviewed by MIT Technology Review to discuss our licensed
technology that was demonstrated to be more effective in treating cancers than existing
alternatives by virtue of the fact that reformulated anti-cancer chemotherapy with mitochondrial
subcellular targeting ligand is able to bypass or evade cancer multi-drug resistance mechanisms
and instruct cancer cells to commit suicide. This is a novel cancer targeting strategy that was
shown to be more effective and made those regular anti-cancer chemotherapies much less toxic
than the non-targeting strategy. We plan to further develop our technologies, take our products
through clinical trials and ultimately bring them to market – so delivering a real breakthrough in
cancer drug treatment. Professor Weissig will be part of that critical process.”
About RCP Therapeutics, Ltd.
RCP Therapeutics, Ltd is a regenerative medicine company focused on commercialising its
proprietary nanotechnologies into large markets with unmet clinical needs and improving patient
The Company is actively developing and optimising pioneering regenerative, curative, and
preventative biomedical technologies and therapeutic products to treat and prevent human
diseases. In early stage studies conducted at the Cleveland Clinic in 2008, RCP’s lead product
candidate, nano SOD, demonstrated highly desirable efficacy in reducing the effects of stroke and
reperfusion injury. The company is hoping to begin Phase 1 clinical trials in 2009. Stroke is the
3rd leading cause of death in the United States and a cause of serious, long-term disability.
About Professor Volkmar Weissig
Volkmar Weissig, Sc.D., Ph.D., Associate Professor of Pharmacology, received his B.S., M.S.
and Ph.D. degrees in Chemistry and his post doctoral Sc.D. degree in Biochemistry and
Pharmaceutical Biotechnology from the Martin-Luther University in Halle (Germany). He
completed several years of postdoctoral fellowships at the Cardiology Research Centre in
Moscow (Russia), at the Academic Department of Medicine at the Royal Free Hospital School of
Medicine in London (UK), at the Institute of Organic Chemistry at the Czechoslovakian Academy
of Science in Prague (CSFR), at the College of Pharmacy and the College of Medicine at the
University of Florida, Gainesville, FL and at Harvard Medical School and Massachusetts General
Hospital in Boston, MA.
Before joining the faculty at Midwestern University, he was an Assistant
Professor of Pharmaceutical Sciences at Northeastern University in Boston, MA. Dr. Weissig
holds 16 patents and has published over 60 research papers, review articles and book chapters,
mostly in the area of nano drug delivery systems. Several of his book chapters have been
translated into Chinese, German and Polish. More recently, he has turned his scientific focus on
Mitochondrial Pharmaceutics, an area he actively has been pioneering for the last 10 years.
He serves as the Associate Editor of the “Journal of Liposome Research” and he is also an Editorial
Board Member of the “Journal of Biomedical Nanotechnology”, of “Medicinal Chemistry” and of
“Cancer Nanotechnology: Basic, Translational, and Clinical Research".. He is frequently invited to
speak at international scientific conferences. In 2004, Dr. Weissig was elected as Vice Chairman
and the following year as Chairman of the American Association of Pharmaceutical Science’s
Northeast Regional Discussion Group (AAPS-NERDG). He also is an active member of the
International Liposome Society, the Mitochondrial Research Society, the Controlled Release
Society, the American Society for Gene Therapy and the American Society for Advancement of